International Journal of Pharma and Bio Sciences
    ISSN 0975-6299

Int J Pharm Bio Sci Volume 11 Issue 4, 2020 (October-December), Pages:136-140

Association of non-tuberculosis mycobacterium infection with CRP level and occurrence of type 2 diabetes


Parvinder Kaur and Anuj Kumar Gupta*

Mycobacterium infection is one of the global threats which are responsible for millions of deaths per year around the world. Major pathogen involved in mycobacterium infection is M. tuberculosis (MTB) however non- tuberculosis mycobacterium (NTM) infection is also responsible for the mortality in recent years. Most promising tools for the diagnosis of mycobacterium are acid-fast bacilli (AFB), tuberculin skin testing and chest X-ray. However these tools cannot differentiate MTB infection from NTM infection. Inflammation has caused NTM which leads to high concentration of CRP in pleural effusion. High level of CRP has several complications including the chance of development of type 2 diabetes mellitus. In this study, a clinical case of man was studied who was diagnosed with Non-tuberculosis mycobacterium (NTM) infection with symptoms same as reported MTB infection. C-reactive protein (CRP), a marker of inflammation was found high in plural fluid after NTM infection. Though the treatment of NTM was completed in 7 months with no relapse however patients got type II diabetes mellitus (T2DM). Occurrence of T2DM could be because of high CRP in the body for a longer time. Though many reports show the positive diagnosis of NTM infection by RT-qPCR however this platform is not available in commercial diagnostic labs as the confirmatory test Genexpert platform is available for the diagnosis of MTB infection. With this report, author described the occurrence of T2DM because of high CRP level present in NTM infection. Further study has been required to establish the correlation between CRP and T2DM pathogenesis. It is recommended to use anti-inflammatory drugs to reduce the CRP in MTB and NTM infection at the initial stage of infection to avoid occurrence of T2DM in patients.

Keywords: CRP, Inflammation, Marker, MTB, Non-tuberculosis mycobacterium, Type II diabetes mellitus
Full HTML:

1.          Xu, G.; Wang, J.; Gao, G. F.; Liu, C. H. Insights into Battles Between Mycobacterium tuberculosis and Macrophages. Protein Cell 2014, 5 (10), 728–736. doi: 10.1007/s13238-014-0077-5.

2.          Griffith, D. E.; Aksamit, T.; Brown-Elliott, B. A.; Catanzaro, A.; Daley, C.; Gordin, F.; Holland, S. M.; Horsburgh, R.; Huitt, G.; Iademarco, M. F.; Iseman, M.; Olivier, K.; Ruoss, S.; von Reyn, C. F.; Wallace, R. J.; Winthrop, K.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am. J. Respir. Crit. Care Med. 2007, 175 (4), 367–416. doi: 10.1164/rccm.200604-571ST.

3.          Jeon, K.; Koh, W. J.; Kwon, O. J.; Suh, G. Y.; Chung, M. P.; Kim, H.; Lee, N. Y.; Park, Y. K.; Bai, G. H. Recovery Rate of NTM from AFB Smear-Positive Sputum Specimens at a Medical Centre in South Korea. Int. J. Tuberc. Lung Dis. 2005, 9 (9), 1046–1051.

4.          Kotwal, A.; Raghuvanshi, S.; Sindhwani, G.; Khanduri, R. Mycobacterium Tuberculosis and Nontuberculosis Mycobacteria Co-Infection: Two Cases from the Sub-Himalayan Region of North India in a Year. Lung India 2017 Sept–Oct, 34 (5), 494–496. doi: 10.4103/lungindia.lungindia_108_17.

5.          Fairchok, M. P.; Rouse, J. H.; Morris, S. L. Age-Dependent Humoral Responses of Children to Mycobacterial Antigens. Clin. Diagn. Lab. Immunol. 1995, 2 (4), 443–447.

6.          Yoon, C.; Semitala, F. C.; Atuhumuza, E.; Katende, J.; Mwebe, S.; Asege, L.; Armstrong, D. T.; Andama, A. O.; Dowdy, D. W.; Davis, J. L.; Huang, L.; Kamya, M.; Cattamanchi, A. Point-of-Care C-Reactive Protein-Based Tuberculosis Screening for People Living with HIV: A Diagnostic Accuracy Study. Lancet Infect. Dis. 2017 Dec, 17 (12), 1285–1292. doi: 10.1016/S1473-3099(17)30488-7.

7.          Yoon, C.; Chaisson, L. H.; Patel, S. M.; Allen, I. E.; Drain, P. K.; Wilson, D.; Cattamanchi, A. Diagnostic Accuracy of C-Reactive Protein for Active Pulmonary Tuberculosis: A Meta-Analysis. Int. J. Tuberc. Lung Dis. 2017 Sept 01, 21 (9), 1013–1019. doi: 10.5588/ijtld.17.0078.

8.          Kassu, A.; Yabutani, T.; Mahmud, Z. H.; Mohammad, A.; Nguyen, N.; Huong, B. T.; Hailemariam, G.; Diro, E.; Ayele, B.; Wondmikun, Y.; Motonaka, J.; Ota, F. Alterations in Serum Levels of Trace Elements in Tuberculosis and HIV Infections. Eur. J. Clin. Nutr. 2006, 60 (5), 580–586.

9.          Tomkins, A. Assessing Micronutrient Status in the Presence of Inflammation. J. Nutr. 2003, 133 (5) (Suppl. 2), 1649S–1655S.  doi: 10.1093/jn/133.5.1649S.

10.       Chase, H. P.; Cooper, S.; Osberg, I.; Stene, L. C.; Barriga, K.; Norris, J.; Eisenbarth, G. S.; Rewers, M. Elevated C-Reactive Protein Levels in the Development of Type 1 Diabetes. Diabetes 2004, 53 (10), 2569–2573. doi: 10.2337/diabetes.53.10.2569.

11.       Lim, L. S.; Tai, E. S.; Mitchell, P.; Wang, J. J.; Tay, W. T.; Lamoureux, E.; Wong, T. Y. C-Reactive Protein, Body Mass Index, and Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2010, 51 (9), 4458-63. doi: 10.1167/iovs.09-4939.

12.       Mugabo, Y.; Li, L.; Renier, G. The Connection Between C-Reactive Protein (CRP) and Diabetic Vasculopathy. Focus on Preclinical Findings. Curr. Diabetes Rev. 2010 Jan, 6 (1), 27–34. doi: 10.2174/157339910790442628.

13.       Bahrmand, A. R.; Madani, H.; Samar, G.; Khalilzadeh, L.; Bakayev, V. V.; Yaghli, M.; babaei, M. H. Detection and Identification of Non-Tuberculous Mycobacterial Infections in 6,472 Tuberculosis Suspected Patients. Scand. J. Infect. Dis. 1996, 28 (3), 275–278. doi: 10.3109/00365549609027172.

14.       Shrestha, N. K.; Tuohy, M. J.; Hall, G. S.; Reischl, U.; Gordon, S. M.; Procop, G. W. Detection and Differentiation of Mycobacterium Tuberculosis and Nontuberculous Mycobacterial Isolates by Real-Time PCR. J. Clin. Microbiol. 2003, 41 (11), 5121–5126. doi: 10.1128/jcm.41.11.5121-5126.2003.

15.       Cai, R. T.; Yu, F. X.; Tao, Z.; Qian, X. Q.; Chen, J.; Lu, H. Z. Routinely Detected Indicators in Plasma Have a Predictive Effect on the Identification of HIV-Infected Patients with Non-Tuberculous Mycobacterial and Tuberculous Infections. Infect. Dis. Pover. 2017, 6(1), 132. doi: 10.1186/s40249-017-0347-6.

16.       Kaur, P.; Qureshi, I.; Khadke, P.; C - Reactive Protein: An Inflammatory Biomarker Present in Multiple Disease Pathogenesis. GLOBAL JOURNAL FOR RESEARCH ANALYSIS 2019, 8 (10), 19–22. doi. doi:10.36106/gjra/5206767.

17.       Kaur, P.; Qureshi, I.; Khadke, P. Analysis of C-Reactive Protein from Different Species Using Computational Analysis and Molecular Dynamics. Int. J. Sci. Res. 2020, 9 (1), 32–34. doi: 10.36106/ijsr.

18.       Nakanishi, S.; Yamane, K.; Kamei, N.; Okubo, M.; Kohno, N. Elevated C-Reactive Protein Is a Risk Factor for the Development of type 2 Diabetes in Japanese Americans. Diab. Care 2003, 26 (10),2754-57. doi: 10.2337/diacare.26.10.2754.

19.       Thorand, B.; Baumert, J.; Kolb, H.; Meisinger, C.; Chambless, L.; Koenig, W.; Herder, C. Sex Differences in the Prediction of type 2 Diabetes Byinflammatory Markers: Results from the Monica/KORA Augsburg Case-Cohort Study, 1984–2002. Diab. Care 2007, 30 (4), 854–860. doi: 10.2337/dc06-1693.

20.       Doi, Y.; Kiyohara, Y.; Kubo, M.; Ninomiya, T.; Wakugawa, Y.; Yonemoto, K.; Iwase, M.; Iida, M. Elevated C-Reactive Protein Is a Predictor of the Development of Diabetes in a General Japanese Population: The Hisayama Study. Diab. Care. 2005, 28 (10), 2497–2500. doi:10.2337/diacare.28.10.2497.

[Download PDF]
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy
Pharmaceutical Fields
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmaceutics
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Novel drug delivery system
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Nanotechnology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacology
Welcome to IJPBS,Pharmaceutics, Novel, drug, delivery, system, Nanotechnology, Pharmacology, Pharmacognosy Pharmacognosy
© Copyright 2009-2015 IJPBS, India. All rights reserved. Specialized online journals by ubijournal. Website by Ubitech Solutions
         Home I Contact I Terms & Conditions